07:24 AM EDT, 09/25/2025 (MT Newswires) -- Eli Lilly ( LLY ) plans to introduce its experimental weight loss pill orforglipron in India, Reuters reported Thursday, citing a senior executive.

Orforglipron, a GLP-1 receptor agonist like Lilly's Mounjaro and Zepbound injectables, has shown better results than Novo Nordisk's (NVO) Rybelsus in lowering blood sugar and weight in patients with type 2 diabetes, the report said.

"There is promise for products like that in India, if it gets approved," Winselow Tucker, president of Lilly India, said at an industry conference in Mumbai, according to Reuters.

The drug has not yet been launched anywhere globally, and while plans to file for approvals in the United States, Britain, the European Union, Japan, and China are underway, it is unclear whether the regulatory process has begun in India, Reuters said.

Lilly did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)